Our finding on that cyclin A1 is involved in the modulation of both ER-α and VEGF pathways may provide novel insights into treatment of breast cancer and may be helpful for designing novel drugs to selectively target invasive breast cancer cells in clinical settings. This evidence concerns the gene VEGFA and breast carcinoma.